CORAL GABLES, Fla., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is pleased to announce the launch of its newly designed website. The site can be accessed at www.catalystpharma.com . "As we continue to make progress and further our plans for the transformation of Catalyst to a company developing novel prescription drugs to treat rare neurological diseases, we felt that it was important to upgrade and revamp our website," said Patrick J. McEnany, Chief Executive Officer of Catalyst. About the Website The site provides an information platform for patients, physicians and investors in an easy to navigate format. The aim of the site is to allow visitors to gain a comprehensive understanding of the Company's drug candidates. Patients and other interested parties can learn about Catalyst's drug candidates, related clinical trials and the science behind them. Website visitors will have an ability to follow the progress of the drug candidates and Company's development in the News and Events sections. Current and potential investors will have the ability to download the latest information on the Company in the Investors section. In keeping with Catalyst's mission to provide treatment for rare neurological diseases through collaboration with patients, physicians, scientists and other constituencies, the new website also offers multiple ways of contacting the Company. All the inputs will be carefully reviewed and will serve as a basis for further development of the website. The ultimate goal is to eventually expand the website into a forum for patients, physicians and other stakeholders to share information, ideas and recommendations. About Catalyst Pharmaceutical Partners Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's syndrome. Catalyst's lead candidate, Firdapse TM for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether any of the Company's product candidates will ever be approved for commercialization and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.
CONTACT: Patrick J. McEnany Catalyst Pharmaceutical Partners Chief Executive Officer (305) 529-2522 email@example.com Melody Carey Rx Communications Group Co-President (917) 322-2571 firstname.lastname@example.org